Gain Therapeutics Financials
| GANX Stock | USD 2.34 0.05 2.18% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.89 | 3.23 |
|
|
The financial analysis of Gain Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Gain Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Gain | Select Account or Indicator |
Understanding current and past Gain Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Gain Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Gain Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Gain Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gain Therapeutics. Check Gain Therapeutics' Beneish M Score to see the likelihood of Gain Therapeutics' management manipulating its earnings.
Gain Therapeutics Stock Summary
Gain Therapeutics competes with Biovie, In8bio, NewAmsterdam Pharma, Cue Biopharma, and Lantern Pharma. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. The company was founded in 2017 and is based in Bethesda, Maryland. Gain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US36269B1052 |
| CUSIP | 36269B105 |
| Location | Maryland; U.S.A |
| Business Address | 4800 Montgomery Lane, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.gaintherapeutics.com |
| Phone | 301 500 1556 |
| Currency | USD - US Dollar |
Gain Therapeutics Key Financial Ratios
| Return On Equity | -2.63 | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K | ||||
| Gross Profit | (11.46 M) | ||||
| EBITDA | (22.17 M) |
Gain Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Other Current Liab | 767.4K | 1.2M | 2.0M | 2.1M | 2.4M | 2.5M | |
| Other Liab | 132.2K | 171.6K | 329.5K | 157.6K | 181.2K | 179.3K | |
| Net Tangible Assets | (450.0K) | 6.2M | 34.6M | 18.7M | 21.5M | 12.8M | |
| Retained Earnings | (7.0M) | (20.9M) | (38.5M) | (60.8M) | (54.7M) | (52.0M) | |
| Accounts Payable | 961.5K | 560.5K | 1.6M | 1.3M | 1.5M | 874.7K | |
| Other Assets | 11.4K | 63.8K | 53.4K | 48.3K | 55.6K | 41.4K | |
| Net Receivables | 66.6K | 113.6K | 103.9K | 242.6K | 279.0K | 292.9K | |
| Other Current Assets | 71.0K | 343.1K | 399.8K | 741.6K | 852.9K | 895.5K | |
| Total Current Assets | 9.0M | 37.7M | 21.1M | 17.8M | 20.4M | 15.9M | |
| Total Assets | 9.6M | 39.0M | 24.1M | 18.6M | 21.4M | 20.2M | |
| Net Debt | (6.2M) | (35.3M) | (6.0M) | (10.8M) | (9.7M) | (10.2M) | |
| Cash | 7.5M | 36.9M | 7.3M | 11.8M | 13.6M | 14.0M | |
| Total Liab | 3.4M | 4.2M | 5.2M | 6.0M | 6.9M | 4.4M | |
| Net Invested Capital | 6.9M | 35.5M | 19.5M | 13.1M | 15.1M | 16.4M | |
| Net Working Capital | 6.9M | 35.2M | 17.0M | 12.8M | 14.8M | 15.7M | |
| Short Term Debt | 145.4K | 542.1K | 337.2K | 348.5K | 400.8K | 324.6K |
Gain Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 5.4K | 4.0K | 93.0K | 142.9K | 164.3K | 172.5K | |
| Net Interest Income | 3.6K | 12.5K | 375.4K | 551.7K | 634.5K | 666.2K | |
| Interest Expense | 20.5K | 189.3K | 117.9K | 247.4K | 284.5K | 298.7K | |
| Total Revenue | 28.9K | 165.0K | 140.1K | 55.2K | 63.5K | 82.7K | |
| Gross Profit | (2.2M) | (7.0M) | 75.9K | (25.2K) | (22.7K) | (23.8K) | |
| Operating Income | (3.5M) | (13.8M) | (17.8M) | (22.3M) | (20.0M) | (19.0M) | |
| Ebit | (3.5M) | (13.8M) | (17.8M) | (22.3M) | (20.0M) | (19.0M) | |
| Research Development | 2.3M | 7.2M | 8.4M | 11.5M | 13.2M | 13.9M | |
| Ebitda | (3.5M) | (13.8M) | (17.8M) | (22.2M) | (20.0M) | (19.0M) | |
| Income Before Tax | (3.6M) | (13.9M) | (17.5M) | (22.2M) | (20.0M) | (19.0M) | |
| Net Income | (3.6M) | (13.9M) | (17.6M) | (22.3M) | (20.0M) | (19.0M) | |
| Income Tax Expense | 5.4K | 4.0K | 93.0K | 79.3K | 91.2K | 95.7K |
Gain Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Gain Therapeutics. It measures of how well Gain is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Gain Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Gain had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Gain Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (20.8K) | (94.2K) | (14.7M) | 7.2M | 6.5M | 6.8M | |
| Change In Cash | 7.2M | 29.4M | (29.6M) | 4.5M | 4.0M | 4.2M | |
| Free Cash Flow | (3.3M) | (12.5M) | (14.8M) | (18.9M) | (17.0M) | (16.1M) | |
| Depreciation | 9.6K | 15.5K | 64.2K | 83.6K | 96.1K | 100.9K | |
| Other Non Cash Items | 8.7K | (34.1K) | (206.9K) | (383.2K) | (344.9K) | (327.6K) | |
| Capital Expenditures | 20.8K | 94.2K | 119.0K | 15.4K | 17.7K | 16.8K | |
| Net Income | (3.6M) | (13.9M) | (17.6M) | (22.3M) | (20.0M) | (19.0M) | |
| End Period Cash Flow | 7.5M | 36.9M | 7.3M | 11.8M | 13.6M | 11.8M | |
| Change To Netincome | (87.5K) | (27.2K) | 1.8M | 1.3M | 1.5M | 1.6M |
Gain Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gain Therapeutics's current stock value. Our valuation model uses many indicators to compare Gain Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gain Therapeutics competition to find correlations between indicators driving Gain Therapeutics's intrinsic value. More Info.Gain Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Gain Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gain Therapeutics' earnings, one of the primary drivers of an investment's value.Gain Therapeutics Systematic Risk
Gain Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Gain Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Gain Therapeutics correlated with the market. If Beta is less than 0 Gain Therapeutics generally moves in the opposite direction as compared to the market. If Gain Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Gain Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Gain Therapeutics is generally in the same direction as the market. If Beta > 1 Gain Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Gain Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gain Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Gain Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Gain Therapeutics March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Gain Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Gain Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Gain Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Gain Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Gain Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.68 | |||
| Information Ratio | 0.1236 | |||
| Maximum Drawdown | 32.31 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 10.75 |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.